Lack of interleukin-4 receptor α chain-dependent signalling promotes azoxymethane-induced colorectal aberrant crypt focus formation in Balb/c mice

Journal of Pathology

Volumn 214, Issue 5, 2008, Pages 603-609

  Ko, C W S ^a,b   Cuthbert, R J ^a   Orsi, N M ^a   Brooke, D A ^a   Perry, S L ^a   Markham, A F ^a   Coletta, P L ^a   Hull, M A ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Aberrant crypt focus; Colorectal cancer; Interleukin 4 receptor; Mouse models; Transforming growth factor

Indexed keywords

AZOXYMETHANE; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 4 RECEPTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL DISEASE; CONTROLLED STUDY; CRYPT CELL; EPITHELIUM CELL; GENE DELETION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AZOXYMETHANE; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-13; INTERLEUKIN-4; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PRECANCEROUS CONDITIONS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41649119141     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2316     Document Type: Article

References (28)

1. Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 2004;53:79-85.
2. Donaldson D, Whitters M, Fitz L, Neben T, Finnerty H, Henderson S, et al. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 1998;161:2317-2324.
3. 2 receptor is involved in induction of TGF β1 production and fibrosis. Nature Med 2006;12:99-106.
4. Olver S, Apte S, Baz A, Kienzle N. The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth? Tissue Antigens 2007;69:293-298.
5. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunol 2000;1:515-520.
6. + T cells. J Clin Invest 2006;116:2777-2790.
7. Park JM, Terabe M, van den Broeke LT, Donaldson DD, Berzofsky JA. Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int J Cancer 2005;114:80-87.
8. Kanai T, Watanabe M, Hayashi A, Nakazawa A, Yajima T, Okazawa A, et al. Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion. Br J Cancer 2000;82:1717-1723.
9. Osawa E, Nakajima A, Fujisawa T, Kawamura YI, Toyama-Sorimachi N, Nakagama H, et al. Predominant T helper type 2-inflammatory responses promote murine colon cancers. Int J Cancer 2006;118:2232-2236.
10. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995;93:55-71.
11. Hurlstone DP, Cross SS. Role of aberrant crypt foci detected using high-magnification-chromoscopic colonoscopy in human colorectal carcinogenesis, J Gastroenterol Hepatol 2005;20:173-181.
12. Venket Rao A, Janezic SA, Friday D, Kendall CW. Dietary cholesterol enhances the induction and development of colonic preneoplastic lesions in C57BL/6J and BALB/cJ mice treated with azoxymethane. Cancer Lett 1992;63:249-257.
13. Mohrs M, Lederman B, Koehler G, Dorfmueller A, Gessner A, Brombacher F. Differences between IL-4 and IL-4Rα deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signalling. J Immunol 1999;162:7302-7308.
14. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003;124:361-367.
15. Roman C, Saha D, Beauchamp RD. TGF-β and colorectal carcinogenesis. Microsc Res Tech 2001;52:450-457.
16. Barnard JA, Warwick GJ, Gold LI. Localization of transforming growth factor beta isoforms in the normal murine small intestine and colon. Gastroenterology 1993;105:67-73.
17. Sheng H, Shao J, O'Mahony CA, Lamps L, Albo D, Isakson PC, et al. Transformation of intestinal epithelial cells by chronic TGF-β1 treatment results in downregulation of the type II TGF-β receptor and induction of cyclooxygenase-2. Oncogene 1999;18:855-867.
18. Guda K, Giardina C, Nambiar P, Cui H, Rosenberg DW. Aberrant transforming growth factor-β signalling in azoxymethane-induced mouse colon tumours. Mol Carcinog 2001;31:204-213.
19. Mohrs M, Holscher C, Brombacher F. Interleukin-4 receptor alpha-deficient BALB/c mice show an unimpaired T helper 2 polarization in response to Leishmania major infection. Inf Immun 2000;68:1773-1780.
20. McGee DW, Vitkus SJD. IL-4 enhances IEC-6 intestinal epithelial cell proliferation yet has no effect on IL-6 secretion. Clin Exp Immunol 1996;105:274-277.
21. Yoshimi N, Sato S, Makita H, Wang A, Hirose Y, Tanaka T, et al. Expression of cytokines, TNFα and IL-1α, in MAM acetate and 1-hydroxyanthraquinone-induced colon carcinogenesis of rats. Carcinogenesis 1994;15:783-785.
22. Robinson SC, Coussens LM. Soluble mediators of inflammation during tumor development. Adv Cancer Res 2005;93:159-187.
23. Kruse S, Japha T, Tedner M, Sparholt SH, Forster J, Kuehr J, et al. The polymorphisms S503P and Q576R in the interleukin-4 receptor α gene are associated with atopy and influence the signal transduction. Immunology 1999;96:365-371.
24. Landi S, Bottari F, Gemignani F, Gioia-Patricola L, Guino E, Osorio A, et al. Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. Eur J Cancer 2007;43:762-768.
25. Kaklamanis L, Gatter KC, Mortensen N, Harris AL. Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer. Br J Cancer 1992;66:712-716.
26. McKay PF, Imami N, Johns M, Taylor-Fishwick DA, Sedibane LM, Totty NF, et al. The gp200-MR6 molecule which is functionally associated with the IL-4 receptor modulates B cell phenotype and is a novel member of the human macrophage mannose receptor family. Eur J Immunol 1998;28:4071- 4083.
27. Andrews A-L, Holloway JW, Holgate ST, Davies DE. IL-4 receptor α is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Immunol 2006;176:7456-7461.
28. Hennekes H, Asadullah K. Strategies for targeting IL-4 as a novel therapeutic approach for the treatment of atopic dermatitis. Curr Med Chem 2002;1:41-53.